Allogeneic Platform

Allogeneic Platform

AvenCell is developing allogeneic, switchable CAR-T cell products that are engineered to overcome the limitations of current gene-edited allogeneic T cell therapies.

Autologous T cell therapies require manufacturing of individualized cell products, which has a high logistical and financial burden and also requires several weeks to manufacture.  In contrast, allogeneic T cell therapies manufactured from healthy donors overcome these bottlenecks:

  • Allogeneic T cell products are readily available “off-the-shelf.”
  • Manufacturing costs per dose are significantly lower for allogeneic T cell products as compared to autologous products.
  • T cells from healthy donors are likely more effective in fighting cancer than immune cells gained from patients with a long disease history or who have undergone multiple cycles of therapy.

However, several immunological challenges must be overcome to provide a safe and persistent cell product with durable efficacy:

  1. Graft-versus-host disease (GvHD) – the attack of the patient’s body by the donor T cells – is a major safety concern. T cell receptors (TCR) expressed by the donor T cells are the key driver of GvHD.
  2. T cells from the patient can recognize allogeneic T cells as “non-self” or “foreign” and initiate the immune defense machinery to eliminate the donor T cells, particularly if these express mismatched HLA proteins. Removal of HLA molecules from the allogeneic donor cell surface can avoid rejection by host T cells.
  3. Allogeneic T cells lacking HLA class I are recognized by the patient’s natural killer cells (NKs) and rapidly eliminated.

In conclusion, both host T cell and NK cell mediated immune rejection can lead to limited persistence of donor T cells and thus have a negative impact on their therapeutic efficacy. Avoidance of rejection by drug-induced host immune suppression is only temporary and promotes the risk of infections.

AvenCell-Integrated-Platforms-v2

AvenCell is leveraging Intellia Therapeutics Inc.’s proprietary allogeneic platform based on CRISPR/Cas9 technology to overcome these challenges. AvenCell has been granted a license to combine Intellia’s CRISPR/Cas9 allogeneic platform with AvenCell’s universal, switchable CAR T-cell platforms. The in-licensed approach applies a novel combination of edits to generate allogeneic T cell products with durable persistence in hosts leading to superior anti-tumor efficacy.

  • Knock-out (KO) of TCR prevents GvHD.
  • KO of HLA class II expression in combination with KO of an HLA Class I protein aim to create allogeneic T cells capable of escaping from recognition by host T and NK cells.

This unique combination enables AvenCell to achieve long-term durability and persistence of its engineered T cells allowing for greater therapeutic efficacy.

Susan Buttler

VP, Clinical Operations

Susan is the Vice President, Clinical Operations for Avencell; she brings over 30 years of experience in Global Clinical Operations to AvenCell’s Clinical Operations team.  Prior to joining Avencell, Susan had multiple senior level roles within the Biotech, Pharmaceutical and CRO organizations.  Susan has experience in leading clinical operations teams to successful study execution and multiple global regulatory submissions. Susan is a graduate of the University of Wisconsin-Milwaukee with a Bachelor of Science in Medical Technology.

Andrew Schiermeier, Ph.D.

Chief Executive Officer

Want to discuss my work or a challenge you’re facing?  Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing?  Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing?  Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing?  Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing?  Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing?  Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing?  Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing?  Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing?  Leave your details and I’ll get back to you.

Want to discuss my work or a challenge you’re facing?  Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing?  Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing?  Leave your details and I’ll get back to you.